Diabetes technology & therapeutics · 2026
Performance of the Fifth Generation of a 16-Day Continuous Glucose Monitoring System in Adults with Diabetes.
Клиническое исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Shichen, Lu Yibing, Ling Hongwei, Zhang Guanqun, Zhang Yanan, Li Xiaoying, Zhao Lin
Аннотация
BACKGROUND: This study evaluated the accuracy and safety of the Anytime 5Pro continuous glucose monitoring (CGM) system, a real-time, factory-calibrated device, over a 16-day period in adults with diabetes.
METHODS: Adult participants with type 1 or type 2 diabetes were recruited from three clinical sites in China. Each participant was equipped with four sensors (one on each upper arm and two on the abdomen) for a period of up to 16 days. To evaluate sensor performance, participants were randomly assigned to one of three 7-hour clinic sessions on days 1 or 2, days 7, 8 or 9, and day 16. During the sessions, the real-time glucose values measured by Anytime 5Pro CGM system were compared with venous blood glucose values measured by the EKF blood glucose detector. Primary endpoints for assessment were the mean absolute relative difference (MARD), the proportion of CGM values within ±20%/±20 mg/dL of reference values, and the percentage of paired points within Zones A and B of the consensus error grids.
RESULTS: In the cohort of 72 participants (287 sensors), the CGM system exhibited an overall MARD of 8.58%, with 96.59% of values within the ±20%/±20 mg/dL criteria. Comparative analysis revealed similar accuracy between arm (MARD: 8.58%; agreement: 97.03%) and abdomen (MARD: 8.58%; agreement: 96.16%) sensor placements. Throughout the 16-day wear period, the ±20%/±20 mg/dL agreement rates remained above 95%, with MARDs ranging from 8.30%-8.88%. Consensus error grid analysis showed 99.99% of points in Zones A and B. No serious adverse events were reported.
CONCLUSIONS: The system demonstrated accurate glucose measurements across the 16-day wear period, irrespective of sensor placement site or glucose concentration.
METHODS: Adult participants with type 1 or type 2 diabetes were recruited from three clinical sites in China. Each participant was equipped with four sensors (one on each upper arm and two on the abdomen) for a period of up to 16 days. To evaluate sensor performance, participants were randomly assigned to one of three 7-hour clinic sessions on days 1 or 2, days 7, 8 or 9, and day 16. During the sessions, the real-time glucose values measured by Anytime 5Pro CGM system were compared with venous blood glucose values measured by the EKF blood glucose detector. Primary endpoints for assessment were the mean absolute relative difference (MARD), the proportion of CGM values within ±20%/±20 mg/dL of reference values, and the percentage of paired points within Zones A and B of the consensus error grids.
RESULTS: In the cohort of 72 participants (287 sensors), the CGM system exhibited an overall MARD of 8.58%, with 96.59% of values within the ±20%/±20 mg/dL criteria. Comparative analysis revealed similar accuracy between arm (MARD: 8.58%; agreement: 97.03%) and abdomen (MARD: 8.58%; agreement: 96.16%) sensor placements. Throughout the 16-day wear period, the ±20%/±20 mg/dL agreement rates remained above 95%, with MARDs ranging from 8.30%-8.88%. Consensus error grid analysis showed 99.99% of points in Zones A and B. No serious adverse events were reported.
CONCLUSIONS: The system demonstrated accurate glucose measurements across the 16-day wear period, irrespective of sensor placement site or glucose concentration.